<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322073</url>
  </required_header>
  <id_info>
    <org_study_id>682-14</org_study_id>
    <nct_id>NCT02322073</nct_id>
  </id_info>
  <brief_title>Inflammation and Obesity-associated Disease</brief_title>
  <acronym>Adipos2</acronym>
  <official_title>Inflammation and Obesity-associated Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Göteborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visceral obesity and adipose inflammation is considered a driving force of obesity-related&#xD;
      systemic disease, e.g. cardiometabolic disease, liver cirrhosis and chronic kidney disease&#xD;
      (CKD). Inflammatory resolution is actively regulated by specialized pro-resolving mediators&#xD;
      (SPMs), including the endogenous eicosanoid LXA4. Impairment of SPMs may underlie development&#xD;
      of obesity-related pathology.We hypothesize that obese patients who develop obesity-related&#xD;
      disease do so because they suffer from impaired endogenous production of pro-resolving&#xD;
      lipids. This will result in aggravated adipose inflammation and fibrosis, which contribute to&#xD;
      the systemic pathologies. We thus wish to investigate adipose inflammation and the&#xD;
      pro-resolving lipid profile of obese subjects with and without obesity associated metabolic&#xD;
      disease. We also aim to investigate whether LXA4, LXB4 and other anti-inflammatory agents&#xD;
      (such as AICAR) can alter the phenotype of human adipose macrophages in ex vivo tissue&#xD;
      culture. We also investigate basic pathways in inflammatory regulation and obesity related&#xD;
      cardiometabolic disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2014</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory status</measure>
    <time_frame>One year</time_frame>
    <description>inflammatory status vs cardiometabolic disease and tissue fibrosis</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <condition>Inflammation</condition>
  <condition>Kidney Disease</condition>
  <condition>Liver Disease</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiometabolic Syndrome</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Lean healthy controls</arm_group_label>
    <description>Healthy controls with BMI 18.5-24.9 Laparoscopic surgery eg cholecystectomy, fundoplication or Heller myotomy and fundoplication or laparoscopic hernia repair.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Obese BMI 35-55 Laparoscopic Roux-en-Y gastric bypass or Sleeve gastrectomy Phenotype according to cardiometabolic status</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic surgery</intervention_name>
    <description>Roux-en-Y gastric bypass or other benign laparoscopic surgery</description>
    <arm_group_label>Lean healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Obese individuals planned for Roux-en-Y gastric bypass or Sleeve gastrectomy surgery and&#xD;
        lean healthy controls planned for elective benign laparoscopic surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese BMI 35-55 kg/m2&#xD;
&#xD;
          -  Lean BMI 18.5-24.9&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical treatment with NSAIDs, corticosteroid treatment, immune-suppressants.&#xD;
&#xD;
          -  Other: smoking, alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ville R Wallenius, MD, PhD.</last_name>
    <phone>+46313421000</phone>
    <email>ville.wallenius@gastro.gu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sahglrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>S41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ville R Wallenius, MD, PhD.</last_name>
      <phone>+46313421000</phone>
      <email>ville.wallenius@gastro.gu.se</email>
    </contact>
    <investigator>
      <last_name>Ville R Wallenius, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

